ALXN1210-PNH-303

ALXN1210-PNH-303

A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With Eculizumab 


Study treatment


Inclusion criteria


Exclusion criteria


Participating sites

Link